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Chikungunya virus (CHIKV) is a virulent re-emerging human
pathogen and one of the leading causes of mosquito-borne
arthralgia in parts of Africa, India and Southeast Asia (Higgs,
2006; Powers & Logue, 2007). In some cases, morbidity has been
unexpectedly high with extensive incapacitation, including
some lethal cases (Higgs, 2006; Josseran et al, 2006; Powers &
Logue, 2007; Queyriaux et al, 2008; Simon et al, 2007). CHIKV
was first isolated in 1953 in Tanzania from infected patients who
often developed a contorted posture owing to debilitating joint
pains (Kondekar & Gogtay, 2006; Lumsden, 1955; Robinson,
1955). However, the re-emergence of CHIKV since 2005 has
caused millions of cases throughout countries in and around the
Indian Ocean and Southeast Asia (Powers & Logue, 2007;
Renault et al, 2007; Thiboutot et al, 2010), and until now
sporadic outbreaks are still ongoing in several countries
inflicting naı¨ve populations (http://www.promedmail.org).
Singapore, for instance, experienced two successive waves of
Chikungunya fever (CHIKF) outbreaks in January and
August 2008 (Leo et al, 2009; Ng et al, 2009; Win et al,
2010). Although there were only 718 laboratory-confirmed
cases reported in 2008 and 341 cases in 2009 (http://www.
moh.gov.sg/mohcorp/publicationsreports.aspx?id=23352,
http://www.moh.gov.sg/mohcorp/publicationsreports.aspx?id
=25254), CHIKF remains a public threat due to the low herd
immunity. Therefore, it may represent a major public health
problem with severe social and economic impact.
CHIKV is one of the 29 recognized species within the genus
Alphavirus in the Togaviridae family (Solignat et al, 2009). The
virus contains a positive-sense, single-stranded, non-segmented
ribonucleic acid (RNA) genome of approximately 11.8 kilobases
in length (Strauss & Strauss, 1994), with a virion diameter of
approximately 70–100 nm (Her et al, 2009; Simizu et al, 1984).
The genome encodes four non-structural proteins (nsP1, nsP2,
nsP3 and nsP4) and precursors of structural proteins comprising
of one capsid protein (C), two envelope surface glycoproteins
(E1 and E2) and two additional small proteins (E3 and 6K)
(Strauss & Strauss, 1994; Teng et al, 2011). Similar to other
alphaviruses, the E1 and E2 glycoproteins are postulated to be
involved in mediating the fusion and interaction with host
receptors during CHIKV infection (Solignat et al, 2009; Voss
et al, 2010).
The virus is generally maintained in a zoonotic cycle that
involves sylvatic and urban CHIKV transmission cycles
(Powers, 2010). Outbreaks occurring in rural countries are
mostly due to sylvatic mosquitoes that are capable of infecting
both primates and humans, with primates being the primary
reservoir for CHIKV (Powers & Logue, 2007). In Asia, CHIKF is
identified mostly as an urban disease with humans as the
primary reservoir (Jain et al, 2008; Tan et al, 2011).
CHIKV causes sudden onset of fever, rashes, arthritis and
other accompanying symptoms (Lumsden, 1955; Robinson,
1955). Following the acute phase of the illness, patients develop
severe chronic symptoms lasting from several weeks to months,
including fatigue, incapacitating joint pain and polyarthritis
(Brighton et al, 1983; Simon et al, 2007). However, as in manywww.embomolmed.org EMBO Mol Med 4, 330–343other arthralgia-causing arbovirus infections, the chronic phase
is observed only in a fraction of the patients (Higgs, 2006;
Kondekar & Gogtay, 2006; Lumsden, 1955; Powers & Logue,
2007; Robinson, 1955). A role for both innate and adaptive
immunity has been proposed (Her et al, 2010; Kam et al, 2009)
but the mechanisms underlying control of viral replication and
dissemination, viral clearance, and acute and chronic disease
severity remain poorly defined. Although anti-CHIKV IgM and
IgG antibodies have been identified in patients (Panning et al,
2008; Yap et al, 2010), the kinetics of the antibody response are
not well characterized.
To date, there is no licensed vaccine against CHIKV, although
potential CHIKV vaccine candidates have been tested in humans
and animals with varying success (Akahata et al, 2010; Edelman
et al, 2000; Harrison et al, 1967, 1971; Levitt et al, 1986; Plante
et al, 2011). As a result, outbreaks are controlled predominantly
by preventing the exposure of people to infected mosquito
vectors (Tan et al, 2011). Therefore, there is a constant need for
novel approaches in rational vaccine formulation for better
efficacies with lesser drawbacks.
Here, we demonstrate the target- and isotype-specificity of the
antibody response against the CHIKV surface antigens by using
plasma obtained during the early convalescent phase of CHIKF
patients (Kam et al, 2012; Win et al, 2010). We showed for the
first time that the early neutralizing IgG3 antibodies dominating
the response are mostly specific for a single epitope, ‘E2EP3’. It
is located at the N-terminus of the E2 glycoprotein proximal to a
furin E2/E3-cleavage site that is conserved inmany alphaviruses
(Ozden et al, 2008). Screening across different patient cohorts
suggests it to be a good serology detection marker for early
CHIKV-specific immune responses. E2EP3-specific antibodies
were also detected in the plasma of infected non-human
primates (NHP), the preferred model system for pre-clinical
studies. Moreover, mice vaccinated by the E2EP3 peptide
showed reduced viremia and only minor joint inflammation
after virus challenge, providing a basis for the design of effective
vaccines against arthralgia-inducing CHIKV and other alpha-
viruses.RESULTS
E2 glycoprotein is the dominant antigen recognized by
CHIKV-infected patients
Surface proteins of RNA viruses are targets of neutralizing
antibodies (Han & Marasco, 2011; Hunt et al, 2010; Murphy &
Whitehead, 2011). In order to identify which of the surface
proteins of CHIKV are recognized, plasma samples obtained
from 30 CHIKV-patients were analysed. The samples were
collected during acutemedian 4 days post-illness onset (pio) and
early convalescent phase (median 10 days pio). Reactivity of
each plasma sample was assessed by western blot using purified
CHIKV virions (Fig 1A) as well as by lysates of cells transiently
expressing recombinant forms of the major CHIKV surface
proteins (capsid, E2 and E1 glycoproteins). Identity of the
expressed protein was validated with antibodies specific for
the respective surface molecule revealing also an accurate 2012 EMBO Molecular Medicine 331
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Figure 1. Antigenic recognition by CHIKV-infected
patients’ samples.
A. Total cell lysates were prepared from transiently
expressed capsid protein (Capsid plasmid), E2
glycoprotein (E2 plasmid) and E1 glycoprotein
(E1 plasmid). Vector transfected (Vector plasmid)
cell lysates were used as negative control. Lysates
and purified CHIKV virions (SGP11 virion) were
subjected to SDS-PAGE gel and probed with a
representative CHIKV-infected patient’s plasma
at a dilution of 1:2000, followed by secondary
human anti-IgG-HRP. Sizes of molecular weight
markers are indicated in the left part of the
diagram.
B. Band intensities corresponding to CHIKV struc-
tural proteins (Capsid, E2 and E1) were analysed
by densitometry for all patient samples (n¼ 30).
Results are expressed as mean-grey value
(MGV) SD. Data are representative of 2 inde-
pendent experiments with similar results.
p<0.001 by Kruskal–Wallis test with Dunn’s
post-test.
332molecular weight of about 31 kDa (capsid), 52 kDa (E2) and
51 kDa (E1) (Supporting information Fig 1A).
We have previously shown that IgG can first be measured at
the early convalescence time of median 10 days pio, a time point
when CHIKV is no longer detectable in the blood (Kam et al,
2012). In line with this observation, no specific IgG-bands were
evident when using plasma from the acute phase 4 days pio
(Fig 1A, left panel), whereas a clear IgG-response was detected
at median 10 day pio (Fig 1A, right panel). Notably, the plasma
stained only one specific band corresponding to the E2
glycoprotein. At this time point, no major reactivity was
observed for the capsid or the E1 protein, which was consistent
for all 30 patients’ samples. Quantification of the scanned
western blots therefore revealed only for E2 bands intensities
that were different from the background (Fig 1B). Thus, in line
with earlier reports on other alphaviruses (Griffin, 1995; Kerr et
al, 1992; Strauss et al, 1991), E2 glycoprotein is the main target
in naturally-acquired immunity in infected patients who just
cleared their viremia.
Epitope mapping of the E2 glycoprotein identifies a linear
epitope proximal to the furin-cleavage site
In order to identify linear epitopes within the E2 glycoprotein, a
peptide library consisting of overlapping peptides was scanned 2012 EMBO Molecular Medicinewith the pooled patients’ plasma (Fig 2A). The library covered
the entire E2 glycoprotein and consisted of 18-mer peptides,
each with an overlap of 10 amino acids. Analysis of pools
combining 5 consecutive peptides revealed that the IgG-
response was most pronounced against the N0-terminal part
of the E2 glycoprotein (Pool P1). Only someminor reactivity was
detected to the other regions of the protein (Pools P2, P10 and
P11) (Fig 2A). Plasma samples were next assayed with the
complete set of single peptides from each of the four active pools
(Fig 2B). We found that the antibodies strongly recognized the
first two peptides of pool 1. In a previous study, we established
that the early IgG response against CHIKV is almost exclusively
driven by antibodies of the IgG3 isotype (Kam et al, 2012).
A very similar picture therefore emerged when anti-IgG3
instead of anti-IgG was used for detection (Fig 2C, Supporting
information Fig 1B). Although the sensitivity of the IgG3
assay is generally weaker, the two peptides of pool 1 (P1-1 and
P1-2) were clearly detectable, showing a slightly stronger titer
for P1-1.
The strong response against the first two peptides suggested
that the epitope (termed here ‘E2EP3’) should be present within
the overlapping part of peptides P1-1 and P1-2. The sequence
alignment revealed that the overlap (STKDNFNVYKATRPY-
LAH) is located proximal to the furin cleavage site. The site isEMBO Mol Med 4, 330–343 www.embomolmed.org
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Figure 2. Epitope mapping of the E2 glycoprotein.
A. CHIKV-infected patient plasma pools (Median 10 days pio) were subjected
to peptide-based ELISA at a dilution of 1:2000, followed by secondary
human anti-IgG-HRP using pooled peptides (P1–P11).
B. The same set of patient plasma pools were subjected to peptide-based
ELISA at a dilution of 1:2000, followed by secondary human anti-IgG-HRP
using both selected peptide pools (P1, 2, 10 and 11) and individual
peptides.
C. Selected individual peptides were re-screened with patients’ plasma pools
at a dilution of 1:200, followed by secondary human anti-IgG3-HRP. Black
solid line represents the mean value of the healthy donors and dotted line
represents the value of mean 6 SD. Values above mean6 SD are con-
sidered positive. Results represent an average of two independent
experiments.required for the proteolytic generation of E2 and E3 glycopro-
teins from the common precursor protein (Ozden et al, 2008)
and the ‘furin loop’ is conserved in alphaviruses (Ozden et al,
2008). The availability of the recent crystal structure of the
CHIKV E1–E2 glycoprotein (Voss et al, 2010) further allowed thewww.embomolmed.org EMBO Mol Med 4, 330–343precise localization of E2EP3 epitope. In the mature E2
glycoprotein (Fig 3A), the amino acids of E2EP3 form the
N-terminal part of the molecule. This region is prominently
exposed on the surface of the virus, forming a stalk that points
away from the virus envelope (Fig 3A and B). Control peptides
from other regions of the E2 glycoprotein did not detect any
reactivity from the patients’ plasma (Supporting information Fig
2A). Using a library of peptides containing a series of alanine-
substituted amino acids (Cunningham & Wells, 1989), we were
able to identify both the core-binding region as well as the key
amino acids recognized by anti-E2EP3 antibodies of patients’
plasma. The result of the alanine-scan (Fig 4A and Supporting
information Fig 3) was in good correlation with the crystal
structure (Fig 4B). Based on this data, the core-binding region of
E2EP3 comprises aa3-10 (STKDNFNVYK), which represents the
exposed part of the sequence (aa1-3 were not resolved in the
crystal structure).
A particularly strong abrogation of binding was observed after
replacing residues K3, N5 andK10. Their amino acid side chains are
either polar (N5) or positively charged (K3, K10), andwere exposed
to solvent in the crystal structure. The substitution of these amino
acids reduced antibody binding to below 40% compared to the
original E2EP3 peptide (Fig 4A). Detailed information on the titers
against the substituted peptides is shown (Supporting information
Fig 3, and a representative video of the E2EP3 epitope analysis is
shown in Supporting information Video 1.
The neutralizing effect of patients’ plasma is directed
predominantly against E2EP3
The neutralizing capacity of CHIKV-specific antibodies in the
plasma was tested in vitro. For this, CHIKV were pre-incubated
with the pools of patients’ plasma before infecting HEK 293T
cells. Immunofluorescence staining followed by single-cell
quantification using the Cellomics high content screen was
used to assess infectivity by determining the number of CHIKV
positive cells. Pooled plasma from infected patients effectively
neutralized CHIKV infection. Here, the infection rate decreased
to approximately 20% of total cells (Fig 5A). The addition of
soluble E2EP3 peptide to the plasma, however, partially
abrogated the neutralization. Blocking with E2EP3 peptide
increased CHIKV infection from 20% to almost 40% (Fig 5A),
verifying that antibodies to E2E3P are strongly neutralizing.
This observation was further confirmed in experiments
where E2EP3-specific IgG3 antibodies were selectively depleted.
Exposure of the patients’ plasma to surface-bound E2EP3
peptide completely removed all E2EP3-specific IgG3, while a
partial depletion was achieved with peptides where the key
amino acids K3, N5 and K10 were alanine-substituted (E2EP3-
specific IgG3was depleted by 30% for peptide K3A/K10A, and by
15% for peptide K3A/N5A/K10A) (Fig 5B). The impact of the
complete or partial depletion of E2EP3-specific IgG3 antibodies
was then tested by comparing the titers of the plasma pools on
whole virus (Fig 5C). The removal of E2E3P-specific antibodies
reduced the total anti-CHIKV IgG3 titer by almost 80%. The
partial removal by peptide K3A/K10A decreased the titer by 40%,
while peptide K3A/N5A/K10A decreased by 20% (Fig 5C). The
drastic reduction in the titer indicates that anti-E2EP3 antibodies 2012 EMBO Molecular Medicine 333
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Figure 3. Localization of the E2EP3 epitope.
A. Schematic diagram showing the localization of
the E2 glycoprotein specific epitope (E2EP3, in
red colour) in the E2 glycoprotein alone based on
structural data retrieved from PDB records: 3N44.
Tertiary structure of E2 glycoprotein is arranged
into three structural domains (E2 domain A,
amino terminal; E2 domain B, centre; E2 domain
C, carboxyl terminal).
B. Schematic diagram showing the localization of
E2EP3 in the protein complex situated at the
surface of the virus based on structural data
retrieved from PDB records: 2XFB. Spatial
arrangement of E1 glycoprotein (in pale yellow
colour) and E2 glycoprotein (in light grey colour)
on the viral membrane surface are indicated
accordingly.
334make up a substantial fraction of the total CHIKV specific IgG3
(Fig 5C).
The removal of E2EP3-specific IgG3 also directly translated
into a reduced neutralization capacity of the plasma pools
(Fig 5D). Depletion of plasma with E2EP3 partly restored virus
infectivity from around 20% to more than 50%. As expected,
only a gradual decrease of the neutralizing efficacy was
observed for the alanine-substituted E2EP3 peptides K3A/
K10A and K3A/N5A/K10A (Fig 5D). Thus, during early
convalescence, E2EP3 specific IgG3 antibodies largely mediate
the neutralizing effect in patients’ plasma.
E2EP3 specific IgG3 is a common marker of early
CHIKV-infection
Atmedian 10 days pio, almost all of the patients from this cohort
were sero-positive for E2EP3 IgG3 antibodies (Supporting
information Fig 4). To further validate the specificity and
versatility of E2EP3 as a suitable early detection target, we
screened plasma samples from another 36 CHIKV-infected
patients collected from a separate cohort together with plasma 2012 EMBO Molecular Medicineobtained from 11 healthy donors (Fig 6). Here, plasma were
again collected during the early convalescent phase (median
10 days pio) and tested for anti-E2EP3 IgG3 antibodies by ELISA
(Fig 6B). Whole virus was used as a reference (Fig 6A). As in the
previous cohort, specific E2EP3-binding was detected in
virtually all CHIKV-infected patients with a clear segregation
from the sero-negative healthy control donors (Fig 6A and B).
Similar results were also obtained in a cohort from Malaysia
where early convalescence samples of median 14 days pio were
collected at outbreaks a few months later (Sam et al, 2009).
Likewise, all of the patients screened were sero-positive for
E2EP3, while no reactivity against the epitope was detected in
healthy donors (Fig 6C and D). Thus, E2EP3 specific IgG3
antibodies appear to be a common early marker for CHIKV-
infections at the population level.
E2EP3 in pre-clinical models: marker and vaccine
Non-human primates (NHP) are the most relevant and
commonly used pre-clinical models for viruses (Higgs & Ziegler,
2010; Labadie et al, 2010; Liu et al, 2007; Morgan et al, 2008). ToEMBO Mol Med 4, 330–343 www.embomolmed.org
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Figure 4. Alanine-scan analysis of E2EP3 by anti-
CHIKV antibodies.
A. Alanine substitutions were constructed at each
position of E2EP3 except the existing alanine
residues. CHIKV-infected patients’ plasma pools
were used to validate the binding capacity.
Plasma pools (Median 10 days pio) were tested in
triplicates at dilutions from 1:2000 to 1:32,000
as indicated in Supporting information Fig 3.
Shown are data representing different dilutions
at 1:4000 and 1:32,000. Results are expressed as
percentage binding capacity relative to the
original E2EP3 sequence (% binding capacity)
SD. Experiments were performed in triplicates.
B. Schematic diagram showing the localization of
the asparagine (N5) and lysine (K10) residues
within the E2EP3 epitope region in the E2 gly-
coprotein based on structural data retrieved from
PDB records: 3N44. The structure for K3 was not
resolved and therefore could not be localized.
Tertiary structure of E2 glycoprotein is arranged
into three structural domains (E2 domain A,
amino terminal; E2 domain B, centre; E2 domain
C, carboxyl terminal). Enlarged image shows the
spatial position of the different amino acid
residues within E2EP3 with N5 and K10 high-
lighted in red.explore whether the E2EP3 epitope is also a main target for the
protective response, plasma samples from CHIKV-infected NHP
were characterized with regards to their reactivity against
E2EP3. Nine days after CHIKV-infection, plasma samples had
already detectable anti-CHIKV IgG titers and importantly, also
detected E2EP3 specifically (Fig 7A and Supporting information
Fig 2B). In in vitro neutralization assays CHIKV-infected NHPs
plasma reduced CHIKV infectivity by 80% (Fig 7B). Addition of
soluble E2EP3 peptide abrogated the inhibitory effect of monkey
plasma samples significantly throughout the whole dilution
series (from 1:100 to 1:3200) when compared to the untreated
plasma samples (Fig 7B). Thus, as in humans, E2EP3 antibodies
are part of the protective CHIKV response in NHPs.
The potential of E2EP3 epitope as a vaccine target was further
assessed in amousemodel (Gardner et al, 2010). For this, C57BL/
6 mice were vaccinated with E2EP3 covalently linked to KLH in
the presence of Freund’s Adjuvant. Mice were primed and
boosted twice with the immunogen (emulsified first with
Complete [CFA] and then with Incomplete Freund’s Adjuvant
[IFA]) over a period of 21 days. Significant anti-E2EP3 titer was
detected 19 days post-vaccination after the 1st boost (Supportingwww.embomolmed.org EMBO Mol Med 4, 330–343information Figs 2C and 5A) and was further increased after the
2nd boost at 27 days post-vaccination (Supporting information
Fig 5B). Importantly, the sera obtained at 27 days post-
vaccination were able to neutralize CHIKV-infection in vitro.
Compared to the PBS-vaccinated control group, infectivity was
reduced by approximately 40% (Fig 8A). Moreover, virus
challenge in mice at 30 days post-vaccination indicated a partial
protection by E2EP3 as viremia was reduced from 4500 to
2000pfu/ml at 2 days post-challenge (Fig 8B). This reduction of
virus titer was also reflected in clinical symptoms used tomonitor
the virus-induced inflammation (Supporting information Fig 5C).
Maximal footpad swelling in the PBS-vaccinated group was more
than twice as that of the E2EP3-vaccinated group (Fig 8C). E2EP3
may therefore be used both as a marker as well as a potential
vaccine component in pre-clinical models for CHIKV therapy.DISCUSSION
In a recent study on the naturally-acquired antibody response in
CHIKV-infected patients, we reported that anti-CHIKV IgG can 2012 EMBO Molecular Medicine 335
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Figure 5. Depletion of anti-E2EP3 antibodies reduces neutralizing activity against CHIKV infection.
A. Anti-E2EP3 antibodies in patients’ plasma pools were specifically blocked by soluble E2EP3 peptide and followed by in vitro neutralization assay as described
in Materials and Methods. Results are expressed as percentage control infection. Data are presented as mean SD. Neutralization assays were performed at
1:500 dilution (n¼ 3). p< 0.05, Mann–Whitney U test.
B. Alanine substituted peptides did not deplete E2EP3-specific antibodies in pooled patients’ plasma. Plasma samples (Median 10 days pio) were incubated with
E2EP3 (K3, N5, K10), E2EP3 with double alanine substitution at lysine residues (K3A, N5, K10A) or triple alanine substitution at lysine and asparagine (K3A, N5A,
K10A) peptides. E2EP3 specific peptide-based ELISA was performed to measure the depletion efficiency. Results are expressed as percentage control IgG3 titer
from non-depleted samples. Data are presented as mean SD. Experiments were performed in triplicates.
C. Depleted samples as described in (B) were subjected to anti-CHIKV IgG3 antibodies detection. Virion-based ELISA was performed as described to measure the
depletion efficiency. Results are expressed as percentage control IgG3 titer from non-depleted samples. Data are presented as mean SD. Experiments were
performed in triplicates.
D. In vitro neutralizing activity of anti-E2EP3 antibodies against CHIKV-infected patients’ plasma samples. E2EP3 specific antibodies from pooled plasma samples
(Median 10 days pio) were depleted by E2EP3 (K3, N5, K10), E2EP3 with double alanine substitution (K3A, N5, K10A) and triple alanine substitution (K3A, N5A,
K10A). Neutralization assays were performed at 1:500 dilution (n¼3). Non-depleted plasma and healthy plasma were used as controls. Results are expressed
as percentage control infection. Data are presented as mean SD. p<0.05; p< 0.001 by one-way ANOVA with Tukey post-test.
336be detected only at the early convalescence phase of median 10
days pio (Kam et al, 2012). At this time point most of the virus
has already been cleared and is usually no longer detectable
in the blood. More surprisingly, we observed that virtually all
anti-CHIKV IgG found at this stage of the disease seems to be
of the IgG3 isotype (Kam et al, 2012). Moreover, IgG3 is one of
the two antibody subclasses that can be readily transmitted
across the placenta (Palmeira et al, 2012), further suggesting
that protection of newborns from CHIKV infections can occur
via maternal immunization (Englund, 2007; Gerardin et al,
2008).While it was expected that the early neutralizing antibody 2012 EMBO Molecular Medicineresponse is targeting the proteins of the envelope of the virus, we
have shown here now that in fact most of these IgG3 antibodies
recognize a single epitope forming a prominently exposed stalk
on the E2 glycoprotein.
When using complete CHIKV virion particles E2 glycoprotein
was the only surface protein that reacted to the IgG of the
patients’ plasma collected during the early convalescent phase.
We (Warter et al, 2011) and others have previously shown that
other structural proteins including the E1 glycoprotein (Cho
et al, 2008a; Kowalzik et al, 2008; Yap et al, 2010) and capsid
(Cho et al, 2008b) are also detected to varying degrees byEMBO Mol Med 4, 330–343 www.embomolmed.org
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Figure 6. Sero-positivity of anti-E2EP3 IgG3 antibodies in CHIKV-infected patients from other cohorts.
A. CHIK virion-based ELISA was used to assess anti-CHIKV IgG titer in CHIKV-infected patients from another Singaporean cohort collected at median 10 days pio
(n¼ 36). Healthy donors’ plasma (n¼ 11) were used as controls. Individual samples were subjected to virion-based ELISA at a dilution of 1:2000, followed by
secondary human anti-IgG-HRP. p<0.001 by Mann–Whitney U test. Experiments were performed in triplicates.
B. CHIKV-infected patients’ and healthy donors’ plasma were screened for IgG3 specific antibodies recognizing E2EP3 in the peptide-based ELISA. Individual
samples were subjected to E2EP3 specific peptide-based ELISA at a dilution of 1:200, followed by secondary human anti-IgG3 isotype HRP. p<0.001 by
Mann–Whitney U test. Experiments were performed in triplicates.
C. CHIK virion-based ELISA were used to assess anti-CHIKV IgG titer in 15 CHIKV-infected patients from another cohort collected in Malaysia at median 14 days
pio. Healthy donors’ plasma (n¼ 11) were used as controls. Individual samples were subjected to virion-based ELISA at a dilution of 1:2000, followed by
secondary human anti-IgG-HRP. p<0.001 by Mann–Whitney U test. Experiments were performed in triplicates.
D. CHIKV-infected patients’ and healthy donors’ plasma were screened for IgG3 specific antibodies recognizing E2EP3 in a peptide-based ELISA. Individual
samples were subjected to E2EP3 specific peptide-based ELISA at a dilution of 1:200, followed by secondary human anti-IgG3 isotype HRP. p<0.001 by
Mann–Whitney U test. Experiments were performed in triplicates. The same set of healthy donors’ plasma comprising of donors from Singapore and Malaysia
were used as controls throughout the study. The y axis is plotted in log 2 scale. Red straight line represents the median of the CHIKV-infected patients’ group
and black straight line represents the median of the healthy donors’ group.patients’ IgGs from patients’ samples collected at later time
points. However, especially at the early phase of infection the E2
glycoprotein is apparently the only major target. At later time
points, contributions by epitopes of other proteins may furtherwww.embomolmed.org EMBO Mol Med 4, 330–343increase the complexity of the patterns of antigenic recognition
(Nowak, 1996). CHIKV represents a ‘novel’ virus for the naı¨ve
population. Most infected individuals did not have any prior
encounters with CHIKV, and therefore lacked the complete 2012 EMBO Molecular Medicine 337
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Figure 7. IgG from CHIKV-infected NHP plasma recognize E2EP3 and
neutralize CHIKV infection in-vitro
A. E2EP3 specific antibodies titers in plasma samples (0, 9 and 13 days pi)
were determined by E2EP3 specific peptide-based ELISA at a dilution of
1:2000. Data are presented as mean SD.
B. Anti-E2EP3 antibodies in CHIKV-infected NHP plasma were specifically
blocked by soluble E2EP3 peptide, and followed by in vitro neutralization
assay as described in Materials and Methods. Results are expressed as
percentage infection relative to 0 dpi. Data are presented as mean SD. A
set of serial dilutions from 1:100 to 1:3200 was made and samples assayed
were performed in triplicates. p< 0.05; p<0.01; p<0.001 by two-
way ANOVA with Bonferroni’s multiple comparisons test.
338CHIKV-specific antibodies. E2EP3 may be an early target since it
is a structural element shared with other alphaviruses (Ozden
et al, 2008).
While E2 glycoprotein was clearly the dominant surface
antigen, the most striking observation was that a vast majority
of the early anti-CHIKV IgG3 antibodies were directed against a
single linear epitope. Depletion experiments indicated that
E2EP3-specific antibodies represented nearly 70 to 80% of the
anti-CHIKV IgG of the patients’ sera (Fig 5C). Published crystal
structure data and alanine scan revealed the precise location of
this dominant epitope. E2EP3 is located at the N-terminus of
the E2 glycoprotein. It is part of the furin-loop and forms a
prominent little stalk facing away from the virus envelope with
sufficient flexibility for antibody recognition. While it almost
appears to be ‘destined’ to be recognized by antibodies, its
surface exposure is likely to be a consequence of the need to be
reached by furin. Furin is a golgi-resident protease (Thomas,
2002) and is also used by various viruses including HIV
(Hallenberger et al, 1992). It is mandatory for the maturation of
alphaviruses where it facilitates cleavage of the p62 precursor 2012 EMBO Molecular Medicineinto E2 and E3 glycoproteins (Heidner et al, 1996; Ozden et al,
2008; Zhang et al, 2003).
We have shown that early anti-CHIKV IgG3 were strongly
neutralizing (Kam et al, 2012). Here, we extended these
findings verifying that E2EP3-specific antibodies are able to
block viral infection (Fig 5). Experiments further showed that
neutralizing antibodies to this epitope were also present in
plasma samples of NHPs (Fig 7). Thus, E2EP3 is important for
viral defence both in humans as well as in the pre-clinical animal
model commonly used for the study of CHIKV infections. For
CHIKV, many studies have used inactivated virus (Tiwari et al,
2009), subunit vaccine formulations (Akahata et al, 2010) or
viral vectors (Wang et al, 2011) with some successes in pre-
clinical models. Notably, E2EP3 is a true linear determinant. In
mice, we could therefore show that short E2EP3 peptides linked
to KLH are indeed able to induce protective antibody responses.
E2EP3 therefore represents an ideal candidate that could be
incorporated in vaccine formulations such as multiple antigenic
peptides (MAPs), recombinant proteins or even virus-like
particles (VLPs) aiming to prevent CHIKV infections. These
formulations would have the advantage to incorporate CHIKV T
helper epitopes for efficient antibody production. As a basic
proof-of-principle, we showed in the mouse model that a simple
peptide formulation was effective at inducing neutralizing
antibodies that not only reduced viremia, but also diminished
viral induced-pathologies such as joint inflammation (Gardner
et al, 2010; Morrison et al, 2011) (Fig 8).
Antibodies to E2EP3 were detected during early convales-
cence after viremia was cleared. They serve as reliable early
serologic markers for CHIKV infections. In three independent
cohorts (2 from Singapore and 1 fromMalaysia), E2EP3-specific
antibodies were detected in almost all the blood samples taken
between 10 and 14 median days pio from infected patients,
whereas none of the control plasma reacted against the epitope.
E2EP3 may therefore be used in diagnostic kits, such as epitope-
based immunochromatographic tests (ICT) (Cuzzubbo et al,
2001; Marot-Leblond et al, 2009). In addition, E2EP3 could also
be used for serology detection in sylvatic infections of primates
just like screening of SIVs-infected animals with peptides in
Africa (Simon et al, 2001; Worobey et al, 2010).
In summary, we established that the naturally-acquired early
IgG3 response against CHIKV is strongly focused on the E2EP3
epitope. As a simple linear epitope, it may open new options for
both diagnostic and prevention of CHIKV infections. Due to the
resurgence of CHIKV and other alphaviruses, interests for
prophylactic vaccines have already regained importance. Such
vaccines would be useful for travellers and/or populations at
risk during outbreaks and E2EP3 could become an integral
component to achieve protection.MATERIALS AND METHODS
Study subjects
Thirty patients who were admitted with acute CHIKF to the
Communicable Disease Centre at Tan Tock Seng Hospital (CDC/TTSH),
Singapore, during the outbreak from August 1 to September 23 2008EMBO Mol Med 4, 330–343 www.embomolmed.org
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Figure 8. Protection against CHIKV challenge in mice vaccinated with E2EP3 peptide.
A. In vitro neutralizing activity of E2EP3-vaccinated mouse sera. Mice were immunized with E2EP3 peptide complex to KLH or PBS Control emulsified with
Complete Freund’s Adjuvant (CFA) subcutaneously, and were boosted two more times with Incomplete Freund’s Adjuvant (IFA). Sera was collected at 27 days
post-vaccination and assayed for in vitro neutralization at a dilution of 1:100 (n¼ 3). Results are expressed as percentage infection relative to PBS Control. Data
are presented as mean SD. p<0.05 by Mann–Whitney U test.
B. Mice immunized with E2EP3 or PBS Control were challenged subcutaneously with 106 PFU CHIKV (SGP11). CHIKV viremia was measured at 2 days post-
challenge by virus plaque assay. The detection limit was 1000 pfu/ml. Data are presented as mean SD. p< 0.05 by Mann–Whitney U test.
C. Disease score measurement. Footpad sizes from day 0 to day 14 post-challenge were quantified by [width thickness]. Footpad swelling (inflammation)
relative to day 0 was obtained with the formula: [(day xday 0) day 0], where x represents footpad sizes from day 1 to day 14. Data are presented as
mean SD. p< 0.05 by Mann–Whitney U test.(Ng et al, 2009; Win et al, 2010), were included in this study. Written
informed consent was obtained from all participants. This study was
approved by the National Healthcare Group’s Domain-specific Ethics
Review Board (DSRB Reference No. B/08/026). Clinical features
definition and clinical samples were as described previously (Ng
et al, 2009; Win et al, 2010). Thirty-six other CHIKF patients were
recruited from the same hospital and a single sample was taken
during admission without further follow up. Serum samples were also
obtained from fifteen CHIKF patients (median 14 days pio) seen at the
University Malaya Medical Centre in Kuala Lumpur in 2008–2009.www.embomolmed.org EMBO Mol Med 4, 330–343Virion-based ELISA
The Singapore strain (SGP11) was isolated from a CHIKF patient (Her
et al, 2010). Purified CHIKV (20,000 virions per ml in PBS; 50ml per
well) were immobilized on 96-well maxisorp microtitre plates (Nunc).
Wells were blocked with PBS containing 0.05% Tween-20 and 5%
non-fat milk (PBST-milk), and plates were incubated for 1.5 h at 378C.
CHIKV-infected human and NHP plasma samples were then diluted at
1:1000 to 1:2000 in PBST supplemented with 2.5% non-fat milk and
incubated for 1 h at 378C. HRP-conjugated goat anti-human IgG
(Molecular Probes), mouse anti-human IgG3 (Molecular Probes), and 2012 EMBO Molecular Medicine 339
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The paper explained
PROBLEM:
Chikungunya fever (CHIKF) is an acute illness with abrupt fever,
skin rash, joint inflammation, and occasional involvement of the
nervous system, heart and liver. It has emerged as an important
viral disease in Asia and the Pacific region. It is caused by
Chikungunya virus (CHIKV), an alphavirus that is transmitted by
infected Aedes mosquitoes. There are no specific or effective
treatments for CHIKF as there are no anti-virals or licensed
vaccines. Patient management and treatment is largely symp-
tomatic relief and primarily anti-inflammatory drugs during
disease onset. The re-emergence of CHIKV has prompted
interests to further characterize the understudied CHIKV and to
devise strategies to halt viral transmission.
RESULTS:
During early disease onset, naturally-acquired anti-CHIKV
antibodies from patients mostly target a linear dominant epitope
‘E2EP3’ located at the N-terminus of the E2 glycoprotein. Up to
80% of anti-CHIKV antibodies are specific against E2EP3 and
removal of anti-E2EP3 antibodies partially reversed the
neutralizing effects. Sero-positivity of E2EP3 validated across
different patient cohorts confirmed that E2EP3 could be a good
serology marker for early CHIKV detection. Moreover, anti-E2EP3
antibodies were also detected from CHIKV-infected non-human
primates. Furthermore, mice vaccinated with E2EP3 peptides
showed better clinical outcomes with reduced viremia and
reduced joint inflammation.
IMPACT:
This study demonstrates that the early naturally-acquired
antibody response is directed against a single epitope, and
provides solid preclinical data that the linear E2EP3 epitope
could play a role in future diagnostic and preventive applications.
340rabbit anti-monkey IgG (Alpha Diagnostic) were used to detect human
and NHP antibodies, respectively. Reactions were developed using
TMB substrate (Sigma-Aldrich) and terminated by Stop reagent
(Sigma-Aldrich). Absorbance was measured at 450 nm. Healthy donor
samples were used as controls. ELISA readings were done in duplicates.
Epitope determination and structural localization
Peptide-based ELISA was performed to screen CHIKV-infected patients’
plasma for viral epitopes using synthesized biotinylated-peptides
(Mimotopes). Eighteen-mer overlapping peptides were generated from
consensus sequence based on alignments of different CHIKV amino
acid sequences (accession numbers: EF452493, EF027139,
DQ443544, EU703760, EF012359, NC004162, FJ445430,
FJ445431, FJ445432, FJ445433, FJ445463, FJ445502 and
FJ445511). Synthesized biotinylated-peptides were dissolved in
dimethyl sulphoxide (DMSO) to obtain a stock concentration of
approximately 15mg/ml. All the peptide samples were screened in
triplicates using plasma from either CHIKV-infected patients or
healthy donors, as well as in the absence of plasma in peptide-based
ELISA assays. Structural data was retrieved from PDB (id: 3N44 and
2XFB) and visualized using the software CHIMERA (Pettersen et al,
2004). Solvent excluded molecular surfaces were generated with the
help of MSMS package (Sanner et al, 1996). Coloring of the E2
domains and orientation of the E1–E2 heterodimer asymmetric unit
relative to the viral membrane are based on previously described data
(Voss et al, 2010).
Alanine scanning
Eighteen peptide sequences were synthesized with substitution of a
native amino acid for an alanine (EMC microcollections GmbH).
Peptides were dissolved in DMSO to obtain a stock concentration of
approximately 15mg/ml. All the peptide samples were screened in
triplicates using plasma from either CHIKV-infected patients or 2012 EMBO Molecular Medicinehealthy donors. Results are expressed as percentage binding capacity
relative to the original E2EP3 sequence peptide.
Affinity depletion of CHIKV anti-E2EP3 antibodies
For affinity depletion of human anti-E2EP3 antibodies, synthetic
biotinylated E2EP3 peptide (EMC microcollections GmbH) was added
at 450ng/well to streptavidin-coated plates (Pierce) and incubated at
room temperature for 1 h in PBS containing 0.1% Tween-20 (0.1%
PBST). Human plasma samples were added and incubated for 25min
at room temperature for absorption. The unbound portion was
collected after 21 rounds of absorption. ELISA analysis was performed
to verify the levels of the antibodies during affinity depletion.
Peptide blocking assay
Synthetic soluble E2EP3 peptide (EMC microcollections GmbH)
(100mg/ml) was mixed with diluted (1:500) heat-inactivated human
plasma or serially diluted (from 1:100 to 1:3200) heat-inactivated
NHP plasma and incubated for 1 h at 378C with gentle agitation
(350 rpm). Samples were then mixed with CHIKV at Multiplicity of
Infection (MOI) 10 and incubated for 2 h at 378C with gentle agitation
(350 rpm). Sero-neutralization assay was performed to verify the
neutralizing activity.
Sero-neutralization assay
Neutralizing activity of antibodies from CHIKV-infected patient
samples, NHP plasma and vaccinated mouse sera were tested in
triplicates and analysed by immunofluorescence-based cell infection
assay in HEK 293T cells. CHIKV was mixed at MOI 10 with diluted
heat-inactivated human plasma, NHP plasma or vaccinated mouse
sera, and incubated for 2 h at 378C with gentle agitation (350 rpm).
Virus-antibody mixtures were then added to HEK 293T cells seeded in
96-well plates (1.0104 cells per well) and incubated for 1.5 h at
378C. Medium was removed, and cells were replenished with DMEMEMBO Mol Med 4, 330–343 www.embomolmed.org
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fixation with 4% paraformaldehyde followed by immunofluorescence
staining. Cells were permeabilized with PBS containing 0.2% Tween-
20 and incubated for 10min at room temperature. Cells were stained
with mouse antibody recognizing CHIKV antigen (Her et al, 2010)
diluted in PBS for 1 h at 378C. This was followed by incubation with
goat anti-mouse secondary antibody conjugated to fluorescein
isothiocyanate (FITC) for 1 h at 378C. Cell nuclei were labelled with
DAPI. Images were acquired and analysed quantitatively by the
Cellomics ArrayScan VTI HCS Reader. Percentage of infectivity was
calculated according to the equation: % Infectivity¼100
(% responder from sero-neutralization group/% responder from virus
infection group).
Rhesus macaques studies
Five-year-old cynomolgus macaques (Macaca fascicularis) were
imported from Mauritius. All animals were negative for SIV, Simian
T-Lymphotropic Virus, Herpes B virus, filovirus, SRV-1, SRV-2, measles,
dengue and CHIKV, and were maintained in a biosafety level 3 facility.
Studies were approved by the regional animal care and use committee
(‘Comite Regional d’Ethique sur l’experimentation animale Ile de
France Sud’, Fontenay-aux-Roses, France), reference number: 07-012, in
accordance with European directive 86/609/EEC. Animals were infected
with 106 PFU (in 1ml PBS) LR2006-OPY1 CHIKV by intravenous (i.v.)
inoculation, as described (Labadie et al, 2010). Animals were bled and
observed daily for one week then twice a week to assess viral
replication, inflammation and clinical signs of infection. No virus could
be detected in plasma samples at 9 and 13 days post-inoculation.
Mouse studies and vaccination
Lyophilized KLH-E2EP3 peptide was dissolved in DMSO (Sigma-
Aldrich) to a working concentration of 5mg/ml. Three-weeks old,
female, C57BL/6J (n¼7) were vaccinated subcutaneously in the
abdominal flank with 100mg of KLH-E2EP3 peptide prepared in
100ml emulsion with 50% Complete Freund’s Adjuvant (CFA) (Sigma-
Aldrich) in PBS. Vaccinated mice were further boosted another two
times at day 14 and day 21 with 50mg of the peptide prepared in
Incomplete Freund’s Adjuvant (IFA) (Sigma-Aldrich). Control mice
(n¼7) were vaccinated with PBS/CFA and PBS/IFA on first vaccination
and subsequent booster shots, respectively. Sera were collected from
all mice at day 19 and day 27 post-vaccination for downstream
E2EP3 peptide-based ELISA. All protocols were approved by the
Institutional Animal Care and Use Committee of the Agency for
Science, Technology and Research (ASTAR), IACUC number: 080383.
At day 30, C57BL/6J mice from E2EP3-vaccinated and PBS-control
groups were inoculated with 106 PFU (in 50ml PBS) SGP11 CHIKV.
Virus was inoculated in the subcutaneous (s.c.) region at the ventral
side of the right hind footpad, towards the ankle. Viremia and degree
of inflammation were monitored. Viremia analysis was performed for
day 2 and day 6 by plaque assays. Hind footpads of mice were
measured daily using a Vernier calliper from day 0 to day 14 post-
infection. Measurements were done for the height (thickness) and the
breadth of the foot and quantified as [height breadth]. Degree of
inflammation was expressed as relative increase in footpad size as
compared to pre-infection with the following formula: [(day x day
0) day 0] where x is the footpad measurements for each respective
day post-infection.www.embomolmed.org EMBO Mol Med 4, 330–343Statistical analysis
Data are presented as mean standard error mean (SEM) or as
mean standard deviation (SD). Differences in responses among
groups at various time points and between groups and controls were
analysed using appropriate tests (Mann–Whitney U test, Kruskal–
Wallis with Dunn’s post-test, One-way ANOVA with Tukey post-test,
Two-way ANOVA with Bonferroni’s multiple comparisons test).
Statistics were performed with GraphPad Prism 5.04.Author contributions
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